DYMELOR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Dec 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYMELOR is an oral small-molecule tablet approved by Eli Lilly in 1964 for an undisclosed indication. The specific mechanism of action and therapeutic class are not publicly detailed in available sources. This legacy product represents a foundational asset from Lilly's mid-20th-century portfolio.
LOE Approaching
Product approaching loss of exclusivity with competitive pressure score of 30/100; expect shrinking brand team and transition focus toward lifecycle management rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DYMELOR currently shows zero linked job openings, reflecting minimal active hiring for brand growth. Career opportunity on this asset is limited and declining; roles that do exist focus on lifecycle extension, compliance, and managed transition rather than expansion or innovation.
Brand ManagerField Sales Representative
Worked on DYMELOR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.